Trial Profile
A Phase II Study of Bevacizumab Plus Docetaxel and Gemcitabine in Subjects With Advanced, Previously Untreated, Non-Squamous Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 18 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Oct 2011 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Oct 2011 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.